Adverse events · postmenopausal women with osteoporosis and CKD stages 5 and 5D
1 finding from 1 review
Adverse events · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients on HD with HCV infection
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
1 finding from 1 review
Adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with aHUS
1 finding from 1 review
no estimate extracted
58 participants
Very low
Adverse events · children and adults with aHUS
1 finding from 1 review
no estimate extracted
100 participants
Very low
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether bovine colostrum changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in all adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events: ESKD · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: ESKD compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Adverse events: infection · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: infection compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review